
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
“For patients who are several years out from treatment for bladder cancer or kidney cancer, I don't think [the shortage is] going to have a clinical impact. For more acute settings, I have tried to rely a little bit more on MR urograms and ultrasound,” says Yair Lotan, MD.
In this interview, Yair Lotan, MD, is a professor of urology, chief of Urologic Oncology, the Jane and John Justin Distinguished Chair in Urology, in honor of Claus G. Roehrborn, MD, and vice chair of clinical affairs at the University of Texas Southwestern Medical Center in Dallas.






